Company Overview and News
Construction sector Maintain neutral: The outlook for the construction sector remains challenging as the federal government is reviewing ongoing infrastructure projects to reduce costs by 20%-33%. Projects that could be affected include the Klang Valley mass rapid transit Line 2 (MRT2) and light rail transit Line 3 (LRT3), Pan Borneo Highway (PBH) and Gemas-Johor Baru Electrified Double Tracking (EDT).
2852 9261 3204 5226 6238 5924 5263 5054 9679 5085 7078
Hock Seng Lee Bhd (Aug 17, RM1.45) Maintain hold with a fair value of RM1.25: We maintain our forecasts, “hold” call, and fair value (FV) of RM1.25 based on 10 times financial year 2019 (FY19) earnings per share (EPS), in line with our benchmark forward target price-earnings ratio of seven to 10 times for small-cap construction stocks.
KUALA LUMPUR (Aug 16): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Econpile Holdings Bhd, Apex Healthcare Bhd, Carlsberg Brewery Malaysia Bhd, Daibochi Bhd, Dialog Group Bhd, Hock Seng Lee Bhd, KPJ Healthcare Bhd, Sarawak Plantation Bhd, Sunway Construction Group Bhd and Warisan TC Holdings Bhd. Econpile Holdings Bhd secured a contract worth RM30.
APEXF KPJHF 5016 7090 6238 5878 5253 5263 2836 5135 7277
KUALA LUMPUR (Aug 16): Sarawak-based infrastructure company Hock Seng Lee Bhd (HSL) saw its net profit jump 44.3% to RM14.12 million in the second quarter ended June 30, 2018 (2QFY18) from RM9.78 million a year ago, on the back of accelerated execution of its mega-projects as they entered mid-phases of construction.
6238 BSMAF 1818
KUALA LUMPUR (Aug 15): Hock Seng Lee Bhd (HSL) shares rose 1.41% in early trade today after it bagged an RM101.19 million contract from Petroliam Nasional Bhd (Petronas) to build the fourth Mara Junior Science College (MRSM) in Sarawak on a 40-acre site in Bintulu. Work starts in September for the 36-month contract.
KUALA LUMPUR: AirAsia Bhd , Kuala Lumpur Kepong Bhd , Hock Seng Lee Bhd (HSL), Pasdec Holdings Bhd , Scomi Group Bhd and Tan Chong Motor Holdings Bhd are among the stocks to watch, according to JF Apex Research.
6912 KLKBY 2445 EXPE 6238 4405 7158
KUALA LUMPUR (Aug 14): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: AirAsia Group Bhd, Batu Kawan Bhd, Kuala Lumpur Kepong Bhd, DKSH Holdings (M) Bhd, Hock Seng Lee Bhd, IHH Healthcare Bhd, Nestlé (Malaysia) Bhd, Pasdec Holdings Bhd, Scomi Group Bhd, Tan Chong Motor Holdings Bhd, Versatile Creative Bhd and YTL YTL Hospitality REIT.
SLLXF 7158 532843 DKSHY 6912 KLKBY 2445 4995 EXPE 5225 FORTIS 6238 5109 4405 1899 Q0F IHHHF 5908 DKSHF
KUALA LUMPUR (Aug 14): Hock Seng Lee Bhd (HSL) has bagged a RM101.19 million contract from Petroliam Nasional Bhd (Petronas) to build a Mara Junior Science College (MRSM) in Bintulu, Sarawak, via an open tender exercise.
6238 BSMAF 1818
Hock Seng Lee Bhd (July 30, RM1.40) Maintain hold with a lower fair value (FV) of RM1.25: The financial year ending Dec 31, 2019 (FY19) to financial year ending Dec 31, 2020 (FY20) earnings forecast downgrade is largely due to a lower assumption for job wins of RM250 million annually (from RM400 million previously) during our forecast period.
KUCHING: Construction and marine engineering-based Hock Seng Lee Bhd (HSL) is set to unveil residential and industrial building projects with a combined gross development value (GDV) of about RM150mil.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...